The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
Celldex reported that its monoclonal antibody barzolvolimab met primary and secondary endpoints in two randomized Phase 3 trials enrolling 1,939 patients with chronic spontaneous urticaria.
The injectable fusion protein dazodalibep met its primary endpoint in the first of two pivotal Phase 3 trials in patients with Sjögren's disease.
Researchers at MIT, Massachusetts General Hospital, and Harvard Medical School have developed RamanOmics, a noninvasive technique pairing Raman vibrational microscopy with single-cell gene expression to profile senescent cells.
Novartis has licensed a preclinical radioligand cancer therapy from Chinese biotech BoomRay Therapeutics, agreeing to an upfront payment and milestones that could reach $900 million alongside future sales royalties.
Viking Therapeutics reported that patients who received its dual GLP-1 and GIP receptor agonist VK2735 maintained 85% of their weight loss after switching to once-monthly dosing.
Vertex Pharmaceuticals reported that inaxaplin, an oral small molecule designed to inhibit APOL1, improved measures on a urine test across two different patient populations with kidney disease.
Contract research and manufacturing provider Syngene International has extended its 25-year partnership with Bristol Myers Squibb through 2035, broadening work across discovery, translational medicine, clinical trials, and manufacturing.
Anthropic has launched its newest frontier model, Opus 5.5, which cuts output token pricing to $20 per million tokens compared to $25 for its predecessor.
San Diego-based Iambic Therapeutics filed for an initial public offering with the US Securities and Exchange Commission to advance its pipeline of AI-designed small molecules.
Otsuka and Ionis Pharmaceuticals reported that their Phase 3 Fusion trial of ulefnersen met its primary endpoint in 73 patients with amyotrophic lateral sclerosis caused by FUS gene mutations.
Weekly injections of enicepatide, an injectable dual GLP-1/GIP receptor agonist acquired through Roche's $2.7 billion purchase of Carmot Therapeutics, reduced HbA1c by 2.65% and body weight by 15.5% at week 48 in adults with Type 2 diabetes.
A computational pipeline builds personalized protein-protein interaction networks for glioblastoma patients by integrating patient-specific target profiles, dependency data, and network controllability analysis.
Researchers computationally designed synthetic transmembrane peptides that bind directly to the apolar, membrane-spanning domain of Toll-like receptor 4 to block inflammatory signaling.
Researchers combined the generative models ESM3, ProteinMPNN, and EvoDiff to design 76 functional carrier domains for non-ribosomal peptide synthetases, the giant multi-part enzymes that bacteria use to assemble complex peptide drugs.
Researchers have developed NanoTS, a deep learning tool designed to identify single nucleotide polymorphisms, or single-letter DNA variations, directly from nanopore RNA sequencing data.
Researchers combined physical simulations with a generative machine-learning model, called latent thermodynamic flows, to map the shifting shapes and folding speeds of flexible RNA molecules.
Researchers have built a molecular foundation model that predicts cryptic binding pockets directly from unliganded, static protein coordinates without running structural simulations.
Researchers built the InterVir atlas using thermal proximity coaggregation to track how protein-protein interaction networks shift over time across five RNA viral pathogens.
DeepSCENIC transfers representations from sequence-to-function deep learning models, such as Enformer and Borzoi, to single-cell multiomic atlases to reconstruct causal gene regulatory networks.
Traffickome maps 754 transport proteins into 11 directed transitions across seven cellular compartments to infer where transmembrane cargo moves using standard proteomic profiles.
Computational biologists created cytokine prodrugs designed from scratch that stay inactive until cleaved by tumor-specific enzymes.
A graph-guided autoencoder called MeRN inferred metabolic pathway activity from single-cell RNA sequencing data to pinpoint why folate deficiency disrupts mouse neural tube closure.
Researchers built an automated design pipeline that translates specified analog computing behaviors into synthetic DNA circuits for mammalian cells.
A mechanistic mathematical model tracking both immune cell infiltration and circulating tumor DNA (ctDNA) sheds light on pseudoprogression, a phenomenon where immunotherapy causes tumors to temporarily swell before shrinking.
Peptides computationally engineered purely to change their secondary structure in response to environmental cues proved to act as potent antimicrobial agents in lab tests.
A language-model-guided computational tool identified specific guanine motifs that govern where RNA polymerase II pauses near gene promoters.